Haizheng Pharmaceutical: In the first half of 2022, net profit was 319 million, an increase of 13.84% year -on -year

On the evening of July 19, 2022, Haizheng Pharmaceutical (600267.SH) issued the announcement of the 2022 Half Annual Performance Express Announcement.

The announcement shows that the company's total operating income from January to June 2022 was 5.737 billion yuan, a decrease of 4.46%over the same period last year; the net profit attributable to shareholders of listed companies was 319 million yuan, an increase of 13.84%over the same period last year.

In the first half of 2022, the company basically completed the mid -year operating goals of the year, and the net profit attributable to shareholders of listed companies achieved a growth of 13.84%, which mainly comes from the growth of net profit of non -recurring profit and loss of non -recurring profit and loss belonging to shareholders of listed companies.

In the first half of 2022, the net profit of deducting non -recurring gains and losses from the shareholders of listed companies increased by 19.26%compared with the same period of the previous year. It mainly benefited from the following factors: the effective control of cost costs and the improvement of operating weekly rotation efficiency. The continuous growth of flow has brought about the effective reduction of interest liabilities, and financing related financial expenses decreased year -on -year; during the same period last year, the all -funded subsidiary Hanhui Pharmaceutical Co., Ltd. (hereinafter referred to as "Hanhui Pharmaceutical") The merger is included in the net profit of the mother. During this report, all Hanhui Pharmaceuticals merged into the net profit of the mother -in -law at 100%.

In the first half of 2022, non -recurring profit and loss belonging to shareholders of listed companies mainly confirmed the related profits of Zhejiang Haizheng Sulikang Biotechnology Co., Ltd.'s strategic reorganization transactions and government subsidy income.

- END -